ABBVIE INC. vs. BridgeBio Oncology Therapeutics, Inc. Common Stock
ABBV
ABBVIE INC.
$250.91 +0.86%
VS BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock
$6.75 -23.76%
ABBVIE INC. and BridgeBio Oncology Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABBV | BBOT | |
|---|---|---|
| Market Cap | $439.62 billion | $710.34 million |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | — |
ABBV leads on 1 of 1 size & scale factors.
Valuation
| ABBV | BBOT | |
|---|---|---|
| P/E Ratio | 70.88 | — |
| Price / Book | -74.66 | — |
| Price / Sales | 6.83 | — |
ABBV and BBOT split the valuation factors evenly.
Profitability
| ABBV | BBOT | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | — |
ABBV and BBOT split the profitability factors evenly.
Dividend
| ABBV | BBOT | |
|---|---|---|
| Dividend Yield | 2.76% | — |
| Payout Ratio | 195.48 | — |
ABBV and BBOT split the dividend factors evenly.
Risk & Sentiment
| ABBV | BBOT | |
|---|---|---|
| Short Interest | 0.85% | 0.05% |
BBOT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, BBOT overview, BBOT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.